5-Amino-1MQ 50MG Capsules (60 count)

Log in to view pricing Apply for provider account
5-Amino-1MQ 50MG Capsules (60 count)
Availability:
In Stock

Product Overview

5-Amino-1MQ (15 mg) • NNMT Inhibitor

5-Amino-1MQ is a selective, membrane-permeable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that influences cellular energy metabolism and methylation balance. NNMT is upregulated in adipose tissue, liver, and skeletal muscle in obesity and metabolic syndrome, where it contributes to NAD+ depletion and impaired energy expenditure.[1–4]

Mechanism of Action & NAD+ Modulation

  • Inhibits NNMT → reduces nicotinamide methylation → preserves intracellular NAD+ for mitochondrial function, sirtuin activity, and cellular energy production.[2–3,5–7]
  • Increases SAM and modulates polyamine flux, supporting energy expenditure and epigenetic regulation.[2–4]

Metabolic & Body-Composition Effects

  • In diet-induced obese mice: dose-dependent reductions in body weight and fat mass, smaller adipocyte size, and improved composition without reduced food intake.[5,8–9]
  • ↑ energy expenditure & fat oxidation; ↓ hepatic steatosis and liver triglycerides; improved liver enzymes and histology; ↓ macrophage infiltration in adipose and liver.[8–10]

Glycemic Control & Insulin Sensitivity

  • Improves oral glucose tolerance, suppresses hyperinsulinemia, and enhances insulin sensitivity in obese mice via higher NAD+/SAM, better mitochondrial function, and pathway modulation for glucose/lipid homeostasis.[2–3,5,8,10–12]

Mitochondrial & Longevity-Linked Pathways

  • Upregulates mitochondrial biogenesis, oxygen consumption, and SIRT1 signaling → improved mitochondrial efficiency and cellular energy.[2–3,6–7,10,13]
  • NAD+ preservation and methylation balance connect NNMT inhibition to healthy-aging mechanisms and potential healthspan benefits (preclinical evidence).[2–3,6–7,13]

PK/Tissue Distribution & Perspective

  • Demonstrates systemic exposure and distribution to adipose, muscle, and liver in animals; favorable PK and oral bioavailability noted.[8,14]
  • Human clinical trials are not yet available; preclinical data support exploration for obesity, metabolic syndrome, T2D, NAFLD, and age-related metabolic dysfunction.[1–4,5,8–13,15–16]

References

  1. Sun WD, Zhu XJ, Li JJ, et al. Front Pharmacol. 2024;15:1410479.
  2. Kraus D, Yang Q, Kong D, et al. Nature. 2014;508:258-262.
  3. Roberti A, Fernández AF, Fraga MF. Mol Metab. 2021;45:101165.
  4. Park J, Shin EJ, Kim TH, et al. Arch Pharm Res. 2024;47(12):893-913.
  5. Neelakantan H, Vance V, Wetzel MD, et al. Biochem Pharmacol. 2018;147:141-152.
  6. Bhasin S, Seals D, Migaud M, Musi N, Baur JA. Endocr Rev. 2023;44(6):1047-1073.
  7. Yaku K, Nakagawa T. Antioxid Redox Signal. 2023;39:1133-1149.
  8. Babula JJ, Bui D, Stevenson HL, et al. Diabetes Obes Metab. 2024;26(11):5272-5282.
  9. Sampson CM, Dimet AL, Neelakantan H, et al. Sci Rep. 2021;11:5637.
  10. Zhang CY, Zhu XJ, Sun WD, et al. Arch Biochem Biophys. 2025;:110558.
  11. Ruf S, Rajagopal S, Kadnur SV, et al. Sci Rep. 2022;12:15440.
  12. Kannt A, Rajagopal S, Kadnur SV, et al. Sci Rep. 2018;8:3660.
  13. Liu A, Zhu XJ, Sun WD, et al. Exp Neurol. 2025;389:115253.
  14. Awosemo O, Neelakantan H, Watowich S, et al. J Pharm Biomed Anal. 2021;204:114255.
  15. Bi SZ, Sun WD, Zhu XJ, et al. Eur J Med Chem. 2025;295:117790.
  16. Gao Y, Martin NI, van Haren MJ. Drug Discov Today. 2021;26(11):2699-2706.

All information provided is for research purposes only.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.